Zydus in milestone COPD launch in India

8 October 2020

Zydus Cadila, part of Indian pharma company Zydus Healthcare, is launching Forglyn pMDI, India’s first pressurized metered dose inhaler (pMDI) with a combination of long acting muscarinic antagonist (LAMA) and long acting beta agonist (LABA) for patients suffering from chronic obstructive pulmonary disease (COPD) in India.

Forglyn pMDI is priced at 495 rupees ($6.75) per pack and has been developed in-house using Zydus’ innovations in formulation technology. The administration of the two drugs, the LABA formoterol fumarate and the LAMA glycopyrrolate, in a single inhalation, will improve outcomes due to the desired synergistic effect of the two drugs and a better adherence to the treatment.

COPD is the third leading cause of death worldwide and, in India, an estimated 55.3 million patients suffer from the condition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK